Neurotech startup Paradromics is set to commence human trials of its brain implant in 2025, intensifying the competition in the emerging brain-computer interface (BCI) market.
This move positions Paradromics against Elon Musk’s Neuralink, which has been at the forefront of public attention in this domain.
Paradromics’ CEO and founder, Matt Angle, in an interview with CNBC Tech, expressed his enthusiasm about the potential of brain-computer interfaces.
Leave a reply